Discovery of Chromane Propionic Acid Analogues as Selective Agonists of GPR120 with in Vivo Activity in Rodents
- 6 December 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 8 (1) , 96-101
Abstract
GPR120 (FFAR4) is a fatty acid sensing G protein coupled receptor (GPCR) that has been identified as a target for possible treatment of type 2 diabetes. A selective activator of GPR120 containing a chromane scaffold has been designed, synthesized, and evaluated in vivo. Results of these efforts suggest that chromane propionic acid 18 is a suitable tool molecule for further animal studies. Compound 18 is selective over the closely related target GPR40 (FFAR1), has a clean off-target profile, demonstrates suitable pharmacokinetic properties, and has been evaluated in wild-type/knockout GPR120 mouse oGTT studies.Keywords
This publication has 26 references indexed in Scilit:
- Beyond PPARs and Metformin2012
- Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseasesTrends in Pharmacological Sciences, 2011
- Globalization of DiabetesDiabetes Care, 2011
- Type 2 diabetes as an inflammatory diseaseNature Reviews Immunology, 2011
- GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing EffectsCell, 2010
- Optimization of a Tertiary Alcohol Series of Phosphodiesterase-4 (PDE4) Inhibitors: Structure−Activity Relationship Related to PDE4 Inhibition and Human Ether-a-go-go Related Gene Potassium Channel Binding AffinityJournal of Medicinal Chemistry, 2003
- Summary of information on human CYP enzymes: human P450 metabolism dataDrug Metabolism Reviews, 2002
- Global and societal implications of the diabetes epidemicNature, 2001
- From Ionic Currents to Molecular MechanismsNeuron, 2000
- Calcium Channel Receptor Binding Studies for Diltiazem and Its Major MetabolitesJournal of Cardiovascular Pharmacology, 1987